A Single-arm, Multicenter, Nilotinib Treatment-free Remission Study in Patients With BCR-ABL1 Positive Chronic Myelogenous Leukemia in Chronic Phase Who Have Achieved Durable Minimal Residual Disease (MRD) Status on First Line Nilotinib Treatment
Status: Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 12 Nov 2019
Price : $35 *
At a glance
- Drugs Nilotinib (Primary)
- Indications Chronic myeloid leukaemia
- Focus Registrational; Therapeutic Use
- Acronyms ENESTFreedom
- Sponsors Novartis; Novartis Pharmaceuticals
- 20 Sep 2019 Planned End Date changed from 28 Feb 2025 to 19 Feb 2025.
- 01 Jul 2019 Results presented in the Novartsi media release.
- 13 Jun 2019 Results presented in a Novartis media release.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History